May 4, 2022 – Seeking to bolster its development of a biocompatible graft that promises to reshape the future of cardiac bypass surgery, Medical 21, a medtech device company, recently announced it has filed a Form 1-A with the U.S. Securities and Exchange Commission (SEC) and is now accepting, from the public, reservations for its $40 million funding round on its website.

May 4, 2022 — While the COVID-19 pandemic transitions through various phases, nuclear cardiology teams should maintain a flexible approach about which testing protocols to follow in different clinical scenarios as well as how to manage their labs, according to a new information statement issued by the American Society of Nuclear Cardiology (ASNC), International Atomic Energy Agency (

May 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S.

May 2, 2022 – Inside embryonic cells, specific proteins control the rate at which genetic information is transcribed from DNA to messenger RNA – a crucial regulatory step before proteins are created. Then, organs develop and hopefully function properly. Those specific “regulatory” proteins are called transcription factors, and they do their thing by binding to specific DNA sequences at just the right time.